{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"3.7","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"From the date of enrollment until the date of disease progression (as determined by standard RECIST), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"AZD2171"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received AZD2171","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression or death, up to 5 years.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}